Inhaled Dry Powder Combinations For Pulmonary Fibrosis

Daniel Green, MS, MBA

Chief Executive Officer

CEO and founder of Hap10 (a UCSF spinout), Enject and DiObex. Strategy and business development consultant to Actelion, AstraZeneca, AcelRx, Curatis, IL2-Rx, La Jolla and Xenon. Earlier at Warner Lambert/Parke-Davis and Roche/Genentech (US, Switzerland, Netherlands).

Dave Stack, BS, RPh

Chairman

Emeritus Chairman and former CEO of Pacira Biosciences, which he led for 16 years as Chairman and CEO. Under his leadership Pacira built a portfolio of three opioid-sparing commercial products. He announced his retirement in September 2023 and stayed on as a consultant through August 2025. Former CEO and director of The Medicines Company. Earlier at MPM Capital, Innovex, Immunomedics and Roche.

John Patton, MS, PhD

Chief Scientific Officer and Director

Founder of Inhale Therapeutics (now Nektar). Co-founder and Executive Chairman of iPharma, which Kindeva acquired in 2022, and head of Kindeva's Scientific Advisory Board since. Co-founder, chairman or director of Halozyme, Saegis (acquired by Lundbeck) and InCarda Therapeutics. Has founded or co-founded six drug delivery companies, with more than 100 publications and more than 40 patents. Winner of the 2024 Charles G. Thiel Award from the Respiratory Drug Delivery Conference, given to one scientist every two years for pioneering work in respiratory drug delivery.

Toby Maher, MD, PhD

Chair, Scientific Advisory Board

Professor of Clinical Medicine and Director of Interstitial Lung Disease at the Keck School of Medicine of USC. Over 20 years specializing in all forms of pulmonary fibrosis. Previously led the ILD unit at Royal Brompton Hospital, London, and has been involved in more than 100 trials from phase 1b to phase 4. Trained at the University of Southampton, Imperial College London (MSc, respiratory medicine) and University College London (PhD), and is a Fellow of the Royal College of Physicians.

Danforth Miller, PhD

Formulation Development

Engineer, scientist and inventor with about 25 years in particle engineering for pulmonary delivery. Led early-phase preclinical and clinical development at Inhale (Nektar), Novartis, Respira and Cystetic Medicines. Author of 30+ scientific publications and holder of nine issued patents.

Natalie McClure, PhD

Regulatory Affairs, Development

Regulatory and development experience at Adamas, Cerimon, Tularik/Amgen, Intrabiotics, Matrix and Syntex. Listed with the UC Berkeley Drug Development Seminar, Principles of Regulatory Affairs in Drug Development.

Hilary Sheevers, PhD

Toxicology and Regulatory

Toxicology and regulatory strategy consultant at Akkeri Drug Development Consulting, advising on nonclinical safety, drug development planning and licensing due diligence. Former FDA (CDER) regulator and former worldwide director at J&J/Janssen. Founder and president of Aclairo Pharmaceutical Development Group. PhD in pharmacology and toxicology, University of Arizona, where she serves on the National Advisory Board of the College of Pharmacy.

Bruce Carlson, BS (Eng), MBA

VP Finance and Chief Financial Officer

Finance leader with prior roles at Hap10, Enject, DiObex, ARYx, NovaDermis and Warner Lambert/Parke-Davis.

Kalev Kask, PhD

Clinical Operations

Founder and former CEO of EGeen International, a clinical research organization. Former senior scientist at AGY Therapeutics, with a post-doc at the Max Planck Institute. Studied at Stockholm University.

Gerald Swiss, MS, JD

Intellectual Property Strategist

Retired partner (partner emeritus) at Foley & Lardner LLP, with about 35 years of intellectual property experience in the biopharmaceutical, life science and medical device fields. Focused on patent strategy for small molecules, chemical processes, enzymes and devices, including international strategy for lead compounds, due diligence, freedom to operate and validity analyses. Began his career as a medicinal research chemist at Schering Corporation. BS, University of Notre Dame; MS in organic chemistry, University of Chicago; JD, Seton Hall University.

Mercedes Meyer, PhD, JD

Patent Attorney

Patent attorney at Banner Witcoff representing life science and technology companies, with an extensive biotechnology and pharmaceutical practice in patent management, prosecution, opinions and due diligence. Also handles patent reexaminations and inter partes matters. Holds a doctorate in virology and a degree in chemistry. Received the Intellectual Property Owners Association's 2023 Carl B. Horton Distinguished Service Award, and is a Fellow of the American Intellectual Property Law Association.